Israel Englander’s Aimmune Therapeutics AIMT Stock Holding History

Israel Englander’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-464,696	Closed	-$16K	–	5855
2020 Q3	$16K	Buy	464,696 +244,537	+111%	+$5.21M	0.02%	927
2020 Q2	$3.68M	Sell	220,159 -211,082	-49%	-$3.58M	0.01%	2044
2020 Q1	$6.22M	Buy	+431,241	New	+$11M	0.01%	1170
2019 Q4	–	Sell	-254,928	Closed	-$7.13M	–	4831
2019 Q3	$5.34M	Buy	+254,928	New	+$5.2M	0.01%	1749
2018 Q4	–	Sell	-105,551	Closed	-$2.88M	–	4388
2018 Q3	$2.88M	Sell	105,551 -11,075	-9%	-$313K	﹤0.01%	2170
2018 Q2	$3.14M	Buy	116,626 +31,490	+37%	+$964K	﹤0.01%	2099
2018 Q1	$2.71M	Buy	+85,136	New	+$3M	﹤0.01%	2153

Israel Englander's AIMT Position: Q4 2020 in Review

Israel Englander sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 464,696 shares — an estimated $16K sold.

Israel Englander first reported a position in AIMT in Q1 2018 and held it in 7 quarters. The position peaked at $6.22M in Q1 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Israel Englander reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Israel Englander sold 464,696 Aimmune Therapeutics shares in Q4 2020, an estimated $16K.
Israel Englander first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 7 quarters.
Israel Englander's Aimmune Therapeutics position peaked at $6.22M in Q1 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Millennium Management's 13F filing for Q4 2020, filed 16 Feb 2021.